Jerusalem stem cell cancer therapy developer Gamida Cell Ltd. has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC) to raise $69 million on Nasdaq at a company valuation of $300 million “before money.” The IPO will take place in the coming few weeks.
BMO Capital Markets and RBC Capital Markets are serving as joint book-running managers for the proposed offering. Needham & Company and Oppenheimer & Co are acting as co-managers for the proposed offering.
Gamida Cell strengthened its Board of Directors with the appointment of Robert Blum as chairman of the board. Robert Blum is president and chief executive officer of Cytokinetics, Inc. chairman of Gamida Cell’s board of directors. Julian Adams, Ph.D., Gamida Cell’s chief executive officer and previous chairman, will remain on the company’s board. Jaren Madden was also as Vice President, Investor Relations and Corporate Communications.
Gamida Cell is currently enrolling patients in a Phase III clinical trial in 120 patients with various hematologic malignancies, including high risk leukemias such as acute myeloid leukemia, or AML, acute lymphocytic leukemia, or ALL, chronic myeloid leukemia, or CML, myelodysplastic syndrome, or MDS and lymphomas.
To date, Gamida Cell has raised over $130 million including $40 million in June 2017 at a company value of $160 million.
About Gamida Cell
Gamida Cell is a clinical-stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is developing a diverse pipeline based on its nicotinamide-, or NAM, -based cell expansion technology, addressing limitations of current cell therapies to provide new treatment alternatives for patients. To learn more about Gamida Cell, including current clinical studies, please visit gamida-cell.com